Insights on the global Implantable Cardiac Rhythm Management Device Market to 2030

Company logo

Company logo

Global Implantable Heart Rhythm Management Devices Market

Global Implantable Heart Rhythm Management Devices Market

Global Implantable Heart Rhythm Management Devices Market

Dublin, June 3, 2022 (GLOBE NEWSWIRE) – The Implantable Cardiac Management Device Market Size, Share Analysis Report and Trends by Product (Pacemakers, ICDs, CRTs), by End Use (Hospitals, Specialty Cardiac Centers), by Region, and Segment Forecast, 2022-2030 Report added to ResearchAndMarkets.com Show.

The global market for Implantable Cardiovascular Management Devices is expected to reach USD 28.9 Billion by 2030. The market is expected to expand at a compound annual growth rate of 6.2% from 2022 to 2030. The number of elderly people in the world exposed to cardiovascular diseases is increasing. Hematology, accurate demand, and effective diagnosis of these diseases are factors that contribute to the growth of implantable CRM devices.

Cardiac disorders are one of the leading causes of mortality worldwide, with a large proportion of the population experiencing some form of heart disorder in their lifetime. While the older population is at greater risk, the prevalence of CVD is increasing in the younger generation as well. Tight schedules and busy lifestyles are major factors for high blood pressure among individuals. Several implantable devices are used to improve the functioning of the heart, including defibrillators, ICDs, and cardiac resynchronization therapy (CRT) devices. Pacemakers are the most commonly implanted devices for conduction and sinus disorders. CRTs and ICDs are relatively new and include better technology than their older counterparts.

The COVID-19 pandemic negatively impacted the market, particularly the ICD devices market, with demand and sales declining during 2020. Sales improved as hospitals resumed elective surgeries. However, the development of COVID-19 in several key markets continued to create uncertainty during the year. For example, Abbott reported an improvement in its hospital-based business during the second and third quarters of 2020. However, improvement trends waned or were negatively affected during the fourth quarter of 2020 due to the sudden increase in COVID-19 cases and hospitalizations in many of countries. On the other hand, Nihon Kohden reported strong growth in defibrillator sales in 2020, even though sales activity has been halted due to the pandemic.

Cardiac disorders are one of the leading causes of mortality worldwide, with a large proportion of the population experiencing some form of heart disorder in their lifetime. While the older population is at greater risk, the prevalence of CVD is increasing in the younger generation as well. Several implantable devices are used to improve the functioning of the heart, including defibrillators, ICDs, and cardiac resynchronization therapy (CRT) devices. Implantable defibrillators are mainly used for conduction disorders and sinus disorders.

The Implantable Heart Rhythm Management Devices Market Report Highlights:

  • The hospital end-use segment accounted for the largest share of revenue at over 50.0% in 2021. The growth can be attributed to deeper product penetration, higher volume of surgical procedures, and increased patient footfall.

  • The ICDs products segment accounted for the largest share of revenue at over 45.0% in 2021. The cardiac resynchronization therapy devices segment is expected to register the fastest growth during the forecast period.

  • An estimated 85.7 million Americans (roughly 34% of the population) suffer from high blood pressure and hypertension due to stressful lifestyles. Approximately 23.4 million American adults were diagnosed with diabetes in 2017, while an estimated 7.6 million American adults with diabetes went undiagnosed. Globally, the prevalence of diabetes is expected to rise to 7.7% in 2030.

  • The CRT products segment is expected to register the fastest growth rate during the forecast period due to implementation of supportive legislative policies in developed countries, increased awareness and number of product use training programs.

  • North America dominated the market with a revenue share of over 45.0% in 2021. This can be attributed to the increased incidence of cardiovascular diseases, supportive government policies, favorable payment plans, increased awareness and increased number of training programmes.

  • The Asia Pacific region is expected to experience the fastest compound annual growth rate of 6.6% from 2022 to 2030 due to the high prevalence of CVD and rapidly aging population.

Main topics covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Implantable CRM Devices Market Variables, Trends and Scope
3.1 Market dynamics
3.1.1 Market Driver Analysis
3.1.1.1 Increased incidence of cardiac disorders
3.1.1.2 Favorable Payment Policies
3.1.1.3 Growing elderly population base
3.1.1.4 Increasing adoption of a sedentary lifestyle
3.1.2 Market Constraint Analysis
3.1.2.1 Strict regulatory framework
3.2 CRM Devices: Market Analysis Tools
3.2.1 Industry Analysis – Porter’s Five Forces Analysis
3.2.2 PESTLE ANALYSIS
3.2.3 Major deals and strategic alliances
3.2.4 Cardiac practices in the United States
3.2.5 Number of cardiologists and electrophysiologists in the United States
3.2.6 Implantable loop recorders (ILR)

Chapter 4 Analysis of the Impact of COVID-19
4.1 Analysis of the spread of COVID-19
4.2 Current Impact and Future Scenario
4.3 Impact on companies

Chapter 5 Implantable CRM Devices Market: Segment Analysis, By Product, 2017-2030 (US$ Million)
5.1 Definition and Scope
5.2 Market share analysis by product type, 2021 and 2030
5.3 Global Implantable CRM Devices Market, by Product, 2017 to 2030
5.4 Market Size, Forecast and Trend Analysis, 2017 to 2030
5.4.1 Pacemaker
5.4.1.1 Pacemaker, 2017-2030 (US$1 million)
5.4.2 Defibrillators
5.4.2.1 ICD Devices, 2017-2030 (US$ million)
5.4.3 CRT
5.4.3.1 CRT, 2017-2030 (US$1 million)

Chapter 6 Implantable CRM Devices Market: Segment Analysis, By End Use, 2017-2030 (US$ Million)
6.1 Definition and Scope
6.2 End-use type market share analysis, 2017 to 2030
6.3 Global CRM Devices Market, by End Use, 2017 to 2030
6.4 Market Size, Forecast and Trend Analysis, 2017 to 2030
6.4.1 Hospitals
6.4.1.1 Hospital Market, 2017-2030 (US$ Million)
6.4.2 Specialized Heart Centers
6.4.2.1 Specialized Heart Centers, 2017-2030 (US$1 million)
6.4.3 Other
6.4.3.1 Others, 2017-2030 (US$1 million)

Chapter Seven Implantable CRM Devices Market: Regional Market Analysis, By Product, End Use 2017-2030 Million USD)

Chapter 8 Implantable Heart Rhythm Management Devices Market – Competitive Analysis
8.1 Classification of market participants
8.1.1. Analysis of the company’s market position
8.1.2. Synergy analysis: key deals and strategic alliances
8.1.3. market leaders
8.1.4. innovators
8.2 List of main companies

Chapter 9 The Implantable Heart Rhythm Management Devices Market – Company Profiles
9.1 Striker
9.1.1 Company Overview
9.1.2 Financial performance
9.1.3 Product measurement
9.1.4 Strategic initiatives
9.2 Schiller
9.2.1 Company Overview
9.2.2 Financial performance
9.2.3 Product measurement
9.2.4 Strategic initiatives
9.3 Medtronic
9.3.1 Company Overview
9.3.2 Financial Performance
9.3.3 Product measurement
9.3.4 Strategic initiatives
9.4 Abbott
9.4.1 Company Overview
9.4.2 Financial performance
9.4.3 Product measurement
9.4.4 Strategic initiatives
9.5 Boston Scientific Company
9.5.1 Company Overview
9.5.2 Financial Performance
9.5.3 Product Measurement
9.5.4 Strategic Initiatives
9.6 Koninklijke Philips NV
9.6.1 Company Overview
9.6.2 Financial performance
9.6.3 Product measurement
9.6.4 Strategic Initiatives
9.7 Zool Medical Company
9.7.1 Company Overview
9.7.2 Financial performance
9.7.3 Product Measurement
9.7.4 Strategic Initiatives
9.8 Biotronik
9.8.1 Company Overview
9.8.2 Financial performance
9.8.3 Product Measurement
9.8.4 Strategic Initiatives
9.9 Nihon Kohden Company
9.9.1 Company Overview
9.9.2 Financial performance
9.9.3 Product Measurement
9.9.4 Strategic initiatives
9.10 Microport Scientific Inc.
9.10.1 Company Overview
9.10.2 Financial Performance
9.10.3 Product Measurement
9.10.4 Strategic Initiatives

For more information about this report visit https://www.researchandmarkets.com/r/o0q5b8

Attached

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900